by Zane-Meyer Thornton
WKU Talisman – January 16, 2020
Shelby Mathews is a 13-year-old girl who lives in Morgantown with her mom, dogs, chickens, peacocks and a potbelly pig. She was diagnosed with Dravet syndrome, a rare form of epilepsy that children develop within the first year of life, when she was 4 months old. Most of the time, children experience developmental issues once the seizures begin, and they have to be on medications for their entire lives, according to the Dravet Foundation.
“She has been on every kind of anti-epileptic drug,” said Mathews’ mother, Kristin Wilcox. “She started taking valium at 4 months of age. Just nothing was working.”
In June 2018, a new medication called Epidiolex was approved by the Food and Drug Administration to specifically treat Dravet syndrome and another similar form of epilepsy called Lennox-Gastaut syndrome in children 2 years of age and older. Epidiolex is an antiepileptic drug derived from CBD found in marijuana. Unlike THC, CBD has no psychoactive properties, so users do not experience the euphoric high that is often equated with marijuana use. Mathews began taking Epidiolex in February 2016.
Read the full article at the WKU Talisman website.